RAD9, phosphorylated (Ser1260)

Référence R0444-70-100ug

Conditionnement : 100ug

Marque : US Biological



R0444-70 RAD9, phosphorylated (Ser1260)

Clone Type
Polyclonal
Host
rabbit
Source
human
Isotype
IgG
Grade
Affinity Purified
Applications
E
Crossreactivity
Hu Ye
Shipping Temp
Blue Ice
Storage Temp
-20°C

Rad9 is required for the MEC1/TEL1-dependent activation of Saccharomyces cerevisiae DNA damage checkpoint pathways mediated by Rad53 and Chk1. DNA damage induces Rad9 phosphorylation, and Rad53 specifically associates with phosphorylated Rad9. Cells have evolved multiple strategies for tolerating genomic damage. The most important of these are numerous repair systems that remove or bypass potentially mutagenic DNA lesions. Another cellular strategy is to delay cell-cycle transitions at multiple points. The genetic control of these delays, termed `checkpoints', was first established in budding yeast where it was shown
that the RAD9 gene functions in G2/M arrest after irradiation with X-rays. Subsequently, it has become clear that Rad9 also functions at the G1/S, intra-S and mid-anaphase checkpoints. Defects in checkpoint regulation can lead to genome instability and, in higher eukaryotes, neoplastic transformation. Rad9 also controls the transcriptional induction of a DNA damage regulon (DDR). Rad9 may also have a pro-apoptotic function. This is suggested in that Rad9 from Schizosaccharomyces pombe (SpRad9) contains a group of amino acids with similarity to the Bcl-2 homology 3 death domain, which is required for SpRad9 interaction with human Bcl-2 and apoptosis induction in human cells. Overexpression of Bcl-2 in S. pombe inhibits cell growth independently of rad9, but enhances resistance of rad9-null cells to methyl methanesulfonate, ultraviolet and ionizing radiation. Rad9 conveys the checkpoint signal by activating Rad53p and Chk1p; is hyperphosphorylated by Mec1p and Tel1p; and is a potential Cdc28p substrate.
Mature yeast Rad9 is reported to have an apparent molecular weight of ~148kDa. The human homolog is reported at 48.5 kD.

Applications:
Suitable for use in ELISA. Other applications not tested.

Recommended Dilution:
ELISA: 1:5000
Western Blot: 1:100-1:500
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and add glycerol (40-50%). Freeze at -20°C. Aliquots are stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Applications
Product Type: Pab|Isotype: IgG|Host: rabbit|Source: human|Concentration: ~0.4mg/ml|Form: Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide. No stabilizing proteins added.|Purity: Purified by immunoaffinity chromatography.|Immunogen: A synthetic peptide corresponding phosphorylated aa1249-1263, ksqmkllerlrsqis, of yeast RAD9 protein (KLH). |Specificity: Recognizes the RAD9 protein, pSer1260. Minimal reactivity was detected against the non-phosphorylated form (Ser1260) of the immunizing peptide. No reactivity is expected against the human or mouse analogs of RAD9.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
A synthetic peptide corresponding phosphorylated aa1249-1263, ksqmkllerlrsqis, of yeast RAD9 protein (KLH).
Form
Supplied as a liquid in PBS, pH 7.2, 0.09% sodium azide. No stabilizing proteins added.
Purity
Purified by immunoaffinity chromatography.
Specificity
Recognizes the RAD9 protein, pSer1260. Minimal reactivity was detected against the non-phosphorylated form (Ser1260) of the immunizing peptide. No reactivity is expected against the human or mouse analogs of RAD9.
References
de la Torre-Ruiz MA, et al. (1998). EMBO J 17(9):2687-98. Fasullo, M., et al. (1998) Mol Cell Biol.;18 (3): 1190–1200. Sun, Z. et al. (1998) Science 281: 272-274. Komatsu K., et al. (2000) FEBS Lett. 481(2):122-6. Schwartz M.F., et al. (2002) Mol Cell 9(5):1055-65.|